WO2025201277 - METHOD FOR TREATING DYSLIPIDEMIA WITH ANGIOPOIETIN-LIKE 3 (ANGPTL3) -TARGETED RNAI AGENTS

National phase entry is expected:
Publication Number WO/2025/201277
Publication Date 02.10.2025
International Application No. PCT/CN2025/084552
International Filing Date 25.03.2025
Title **
[English] METHOD FOR TREATING DYSLIPIDEMIA WITH ANGIOPOIETIN-LIKE 3 (ANGPTL3) -TARGETED RNAI AGENTS
[French] MÉTHODE DE TRAITEMENT DE LA DYSLIPIDÉMIE AVEC DES AGENTS ARNI CIBLANT L'ANGIOPOÏÉTINE 3 (ANGPTL3)
Applicants **
SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD.
Inventors
SHU, Dongxu
SHAO, Pengcheng Patrick
LI, Yuqiong
HE, Yafeng
Priority Data
PCT/CN2024/083497   25.03.2024   CN
PCT/CN2024/124851   15.10.2024   CN
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting3837
EPO Filing, Examination, Granting52348
Japan Filing, Examination, Granting3761
South Korea Filing, Examination, Granting5477
USA Filing, Examination, Granting15590
MasterCard Visa
Total: 81,013
Contact Us
Abstract[English] It relates to methods of inhibiting the expression of an ANGPTL3 gene in a subject, as well as therapeutic and prophylactic methods for treating subjects having a lipid disorder, such as a hyperlipidemia using RNAi agents, e.g., double-stranded RNAi agents, targeting the ANGPTL3 gene.[French] L'invention concerne des méthodes d'inhibition de l'expression d'un gène ANGPTL3 chez un sujet, ainsi que des méthodes thérapeutiques et prophylactiques pour traiter des sujets ayant un trouble lipidique, tel qu'une hyperlipidémie à l'aide d'agents ARNi, par exemple, des agents ARNi double brin, ciblant le gène ANGPTL3.

Rejoining the server...